The Federal Trade Commission settled with 12 corporate entities and four individual defendants marketing bogus cognitive supplement brands Geniux, Xcel, EVO and Ion-Z, using “sham” news sites containing false and unsubstantiated efficacy claims. The FTC announced that its complaint, filed in the US District Court for the Northern District of Ohio, alleges Fred Richard Guerra III, Lanty Paul Gray Jr. Rafat Abbas and Robby Salaheddine owned a web of corporate entities that between August 2012 and January 2017 sold the supplements for between $47 and $57 a bottle. False claims for products included that Geniux could “improve short- and long-term memory,” “increase focus” by as much as 300% and prevent memory loss. Claims were made on sites deceptively formatted as actual news sites. Some employed fake consumer endorsements and attributed the achievements of Stephen Hawking and Elon Musk to Geniux products.
Health And Wellness Market News: FTC Settlement, FDA Alert, UK Ad Reviews
FTC settles with operators of a bogus cognitive supplement sales ring for $26.2m; FDA warns on unapproved at-home head injury tests; and UK advertising regulator says HiSmile claims fail, P&G Always Discreet claims pass.
More from Regulation
More from Policy & Regulation
FDA says “extension affords covered entities the additional time necessary to ensure complete coordination across the supply chain in order to fully implement the final rule’s requirements—ultimately providing FDA and consumers with greater transparency and food safety.”
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
CRN petition argues against general preclusion while NPA petition addressed specifically FDA’s wielding of the provision to prohibit the use of NMN supplements available in US. “FDA has acknowledged that they really can't answer one without answering. The two are inextricably linked,” says CRN CEO Steve Mister.